Clinical Trial Update: A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants [Phase 3]

View source ↗

Summary

A Phase 3 sub-study evaluating cabotegravir and rilpivirine in HIV-1 infected participants has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immunodeficiency Syndrome
• HIV Infection

Drugs mentioned

• cabotegravir (cabotegravir)
• rilpivirine (rilpivirine)

Snippet

Sponsor: ViiV Healthcare | Conditions: Human Immunodeficiency Virus Type 1 (HIV-1) | Phase 3 | Status: COMPLETED | Results posted: 2023-09-18